Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Lung Neoplasms 1

Interventions

pembrolizumab 8Nivolumab 3tislelizumab 2spartalizumab 2SS1(dsFv)PE38 2Ipilimumab 2fludarabine phosphate 1fludarabine 1epacadostat 1entinostat 1bosutinib 1atezolizumab 1aldesleukin 1Quality of Life 1Polymerase Chain Reaction 1Platinum 1Pemetrexed 1Patient Reported Outcome Measures 1Paclitaxel 1Molecular Diagnostic Techniques 1Microarray Analysis 1Interleukin-2 1Immunotherapy 1Immunoenzyme Techniques 1Hyperthermic Intraperitoneal Chemotherapy 1Gene Expression Profiling 1Gemcitabine 1Flow Cytometry 1Fentanyl 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Automobiles × Other solid neoplasm × Clear all
NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
15 enrolled 14 charts
GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡